ghk cu tb 500 bpc 157 Glow (BPC-157/TB-500/GHK-Cu) — IVs in the Keys Heal, Repair, Recover - BPC-157,

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

In addition to vitamin B12 shots, you can take vitamin B12 supplements in capsules, tablets, or even liquids

Beyond their initial intention, GLP-1 receptor agonists have shown effectiveness in helping to regulate appetite and enhance insulin sensitivity, which can help to promote weight loss

Cebrin J, Messeguer A, Facino RM, Garca Antn JM

Minoxidil provides relatively quick initial results because it leverages existing follicular machinery, but its effects remain localized to the application site and require continuous use